Gillian McGovern, Associate Editor

The investigators suggest that early detection and treatment of chronic kidney disease (CKD) in childhood cancer survivors may decrease late complications and mortality.

The formulation allows for individualized treatment in children with adrenocortical insufficiency.

The small molecule effectively blocks cell death effector proteins, potentially rescuing cells from degeneration.

The approval is based on findings from the INSPIRE trial, where treprostinil demonstrated efficacy in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

The authors are optimistic that GADD45A serves as a foundation for therapeutic approaches to slow the progression of heart failure.

After 3 predictive mortality tools demonstrate inefficiency within older adults with advanced chronic kidney disease (CKD), the authors call for the development of tools tailored for this population.

This indication is for adult and pediatric patients aged 12 and older with plaque psoriasis of the scalp and body.

The phase 3 REAL8 trial shows once-weekly Sogroya effectively improves growth in children with growth disorders, offering a promising alternative to daily injections.

The risk of cardiovascular disease (CVD) was higher among those who were exposed to assisted reproductive technology.

Compared with placebo, patients with cholestatic pruritus and primary biliary cholangitis (PBC) receiving linerixibat experienced improved itch and sleep interference.

The authors believe the results may serve as a foundation for hepatitis D virus (HDV) testing among hepatitis B virus surface antigen (HBsAg)-positive specimens.

The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer disease.

The new guidelines urge health care professionals to offer local anesthetics and other medications for intrauterine device (IUD) insertions and other gynecologic procedures.

The FDA approves retifanlimab for advanced anal cancer, offering new hope with improved survival rates and treatment options for patients.

The approved injection contains dihydroergotamine (DHE), which is the same medication used in hospitals, in a ready-to-use device.

The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.

Effectively communicating research findings to patients, health care professionals, and policy payers is necessary for engagement.

Artificial intelligence (AI) can transform rare disease research by leveraging patient data, enhancing evidence generation, and improving communication between patients and health care professionals.

Maternal cardiometabolic issues during pregnancy significantly elevate children's blood pressure, highlighting the need for preventive health measures.

During a panel discussion, 3 experts highlighted ways health care professionals and researchers can help provide patient-centered care.

In approximately 84% of cases, the mask was able to detect if patients had chronic kidney disease (CKD).

The new at-home test aims to increase comfort and screening timeliness through a more accessible method.

These findings demonstrate an association that is independent of the disease’s genetic predisposition.

With the FDA approval, avutometinib/defactinib is now the first and only FDA-approved treatment for patients with recurrent low-grade serous ovarian cancer (LGSOC).

These results build off prior studies which demonstrated effectiveness of Bergen 4-day treatment (B4DT) in patients with panic disorders.

Necrotizing enterocolitis (NEC) is a life-threatening illness that is characterized by the inflammation of the intestinal lining, which can lead to intestinal perforation.

The coronary artery disease (CAD) predictive model help health care professionals tailor personalized treatment methods for patients.

This screening method can help empower patients to better manage their health and seek additional care.

About 62.9% of patients with metabolic dysfunction–associated steatohepatitis (MASH) receiving semaglutide experienced resolution of steatohepatitis without worsening of fibrosis.

Jennifer Guthrie, RPh, district leader at CVS pharmacy describes the different medications to treat allergy symptoms and highlight how CVS stands out when addressing patients’ needs.